Perez de Isla, LeopoldoArroyo-Olivares, RaquelMuñiz-Grijalvo, OvidioDiaz-Diaz, Jose LuisZambon, DanielFuentes, FranciscoSanchez Muñoz-Torrero, Juan FMediavilla, Juan DiegoGonzalez-Estrada, AuroraMiramontes-Gonzalez, Jose Pablode Andres, RaimundoMauri, MartaMosquera, DanielCepeda, Jose MSuarez, LorenaBarba-Romero, Miguel AngelArgüeso, RosaAlvarez-Baños, PilarMichan, AlfredoRomero-Jimenez, Manuel JGarcia-Cruces, JesusPadro, TeresaAlonso, RodrigoMata, Pedro2023-02-082023-02-082019-10-03Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, Diaz-Díaz JL, Zambón D, Fuentes F, et al. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. J Clin Lipidol. 2019 Nov-Dec;13(6):989-996.1933-2874http://hdl.handle.net/10668/14664Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH. The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk. SAFEHEART is a prospective follow-up nationwide cohort study in a molecularly defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in life habits, medication, and ACVEs. A total of 1939 patients were analyzed. Median follow-up was 6.6 years (5-10). The estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67-3.39) and 1.22 (0.54-2.93) at enrollment for ATV and RV, respectively (P  ATV and RV are 2 high-potency statins widely used in FH. Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AtorvastatinFamilial hypercholesterolemiaLong-term prognosisRosuvastatinAdultAgedAtorvastatinCholesterol, LDLCohort StudiesDrug Therapy, CombinationEzetimibeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedProspective StudiesRosuvastatin CalciumTreatment Outcomeresearch article31706904open accessAtorvastatinaEzetimibaHiperlipoproteinemia Tipo IIHidroximetilglutaril-CoA ReductasasRosuvastatina CálcicaLDL-Colesterol10.1016/j.jacl.2019.10.005http://www.lipidjournal.com/article/S1933287419302892/pdf